EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieStudienprotokollOpen Access · CC BY 4.0

Understanding Glymphatic’s Role In Proteinopathies (GRIP): A single centre case-control study protocol

Sofie Lysholm Lian, Tryggve Holck Storås, Ebba Müller Gløersen, Grethe Løvland, Einar Hopp iD, Ingrid Mossige iD, Markus Hovd iD, Hilde Thelle Uggerud, Kristin Reimers Kardel, Heidi A Bye, Anne Lise Buset, Kirsten Valdmanis und 9 weitere

PLOS One · 29.10.2026 · 21 (10) · e0360617

DOI: 10.1371/journal.pone.0360617 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift PLOS One, online erschienen am 29.10.2026. Verfasst von Sofie Lysholm Lian und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Glymphatic System, Parkinson Disease, Alzheimer Disease, Lewy Body Disease. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nasjonalforeningen for Folkehelsen, Helse Sør-Øst RHF, European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD), Parkinson’s disease (PD), and dementia with Lewy bodies (DLB) are proteinopathies characterized by pathological accumulation of amyloid beta, phosphorylated-tau, and alpha-synuclein. Impaired clearance of these proteins is thought to contribute to disease pathogenesis, whereas preserved or enhanced clearance may be compensatory. Beyond intracellular degradation within neurons and glial cells, an extracellular clearance pathway, the glymphatic system, facilitates cerebrospinal fluid flow into perivascular spaces, exchange with interstitial fluid, and subsequent clearance from the brain. Glymphatic transport may therefore be critical for removal of excess proteins and metabolic waste, and its dysfunction could promote protein aggregation and neurodegeneration. The Glymphatic’s Role In Proteinopathies (GRIP) study is an observational case-control imaging and biomarker study comparing glymphatic clearance in patients with AD, PD, and DLB versus healthy controls. We aim to recruit 70 participants: PD (n = 20), DLB (n = 10), AD (n = 20), and age- and sex-matched healthy controls (n = 20). The AD group will be stratified by pathology, with half amyloid-positive/tau-negative (A + T-) and half amyloid- and tau-positive (A + T+). The PD group will be stratified by disease duration. Participants will undergo baseline MRI followed by intrathecal injection of gadobutrol (0.25 mmol) and serial MRI at 5, 24, 48, and 72 hours. Influx and efflux of tracer will be modeled from T1 signal changes. Blood will be sampled repeatedly from 1 to 72 hours; cerebrospinal fluid will be collected at baseline. Individual glymphatic clearance will be estimated using population pharmacokinetic methods, where gadobutrol serves as a tracer. Sleep will be monitored with triaxial accelerometry and sleep diaries. The primary outcome is group differences in glymphatic clearance metrics between each disease group and controls; secondary analyses will explore associations with cognition, disease severity and duration, sleep quality, and cerebrospinal fluid protein levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glymphatic SystemParkinson DiseaseAlzheimer DiseaseLewy Body DiseaseHumansCase-Control StudiesFemaleMaleAgedtau ProteinsBiomarkersAmyloid beta-Peptidesalpha-SynucleinMagnetic Resonance Imaging

Substanzen

tau ProteinsBiomarkersAmyloid beta-Peptidesalpha-Synuclein

Autor:innen und Institutionen

  • Department of Neurology, Oslo University Hospital, Oslo, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • The Intervention Centre, Oslo University Hospital, Oslo, Norway.
  • Department of Physics and Computational Radiology, Oslo University Hospital, Oslo, Norway.
  • K.G. Jebsen Centre for Brain Fluid Research, Oslo, Norway.
  • Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Einar Hopp, Ingrid Mossige, Markus Hovd, Anne Rita Øksengård, Kaja Nordengen

Förderung

  • Nasjonalforeningen for Folkehelsen
  • Helse Sør-Øst RHF
  • European Research Council
  • Stiftelsen Kristian Gerhard Jebsen

Zitieren

APA

Lian, S. L., Storås, T. H., Gløersen, E. M., Løvland, G., Hopp, E., Mossige, I., Hovd, M., Uggerud, H. T., Kardel, K. R., Bye, H. A., Buset, A. L., Valdmanis, K., Knapskog, A. B., Øksengård, A. R., Fladby, T., Nilsen, K. B., Mardal, K. A., Ringstad, G., Eide, P. K., …, & Nordengen, K. (2026). Understanding Glymphatic’s Role In Proteinopathies (GRIP): A single centre case-control study protocol. PLOS One, 21(10), e0360617. https://doi.org/10.1371/journal.pone.0360617

Vancouver

Lian SL, Storås TH, Gløersen EM, Løvland G, Hopp E, Mossige I, et al. Understanding Glymphatic’s Role In Proteinopathies (GRIP): A single centre case-control study protocol. PLOS One. 2026;21(10):e0360617. doi:10.1371/journal.pone.0360617

BibTeX
@article{Lian2026,
  author = {Lian, Sofie Lysholm and Storås, Tryggve Holck and Gløersen, Ebba Müller and Løvland, Grethe and Hopp, Einar and Mossige, Ingrid and Hovd, Markus and Uggerud, Hilde Thelle and Kardel, Kristin Reimers and Bye, Heidi A and Buset, Anne Lise and Valdmanis, Kirsten and Knapskog, Anne Brita and Øksengård, Anne Rita and Fladby, Tormod and Nilsen, Kristian Bernhard and Mardal, Kent-André and Ringstad, Geir and Eide, Per Kristian and Toft, Mathias and Nordengen, Kaja},
  title = {Understanding Glymphatic’s Role In Proteinopathies (GRIP): A single centre case-control study protocol},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {10},
  pages = {e0360617},
  doi = {10.1371/journal.pone.0360617}
}
Kostenlos starten →